These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine. Dillon KA; Putnam KG; Avorn JL JAMA; 1997 Oct 22-29; 278(16):1320. PubMed ID: 9343461 [No Abstract] [Full Text] [Related]
24. Further cases of valvular heart disease associated with fenfluramine-phentermine. Graham DJ; Green L N Engl J Med; 1997 Aug; 337(9):635. PubMed ID: 9280830 [No Abstract] [Full Text] [Related]
25. Appetite-suppressant drugs and valvular heart disease. Shapiro S N Engl J Med; 1999 Feb; 340(6):477-8; author reply 478-80. PubMed ID: 9988622 [No Abstract] [Full Text] [Related]
28. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. Mark EJ; Patalas ED; Chang HT; Evans RJ; Kessler SC N Engl J Med; 1997 Aug; 337(9):602-6. PubMed ID: 9271482 [No Abstract] [Full Text] [Related]
29. Dose effect of fenfluramine-phentermine in the production of valvular heart disease. Tovar EA; Landa DW; Borsari BE Ann Thorac Surg; 1999 Apr; 67(4):1213-4. PubMed ID: 10320298 [No Abstract] [Full Text] [Related]
30. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]. Goldstein SE; Levy Y; Shoenfeld Y Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459 [TBL] [Abstract][Full Text] [Related]
31. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087 [TBL] [Abstract][Full Text] [Related]
32. Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go. Vaughan SF J Natl Med Assoc; 2002 Aug; 94(8 Suppl 2):C2-3. PubMed ID: 12185996 [No Abstract] [Full Text] [Related]
33. Dexfenfluramine, fenfluramine, and phentermine for the treatment of morbid obesity. Torretta LK J Am Acad Nurse Pract; 1997 Aug; 9(8):389-94, quiz 395-7. PubMed ID: 9325813 [No Abstract] [Full Text] [Related]
34. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086 [TBL] [Abstract][Full Text] [Related]
35. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography. Roldan CA; Gelgand EA; Decker P; Prasad A; Shively BK Am J Cardiol; 2002 Dec; 90(11):1269-73. PubMed ID: 12450616 [No Abstract] [Full Text] [Related]
36. The treatment of obesity with drugs. Hirsch J Am J Clin Nutr; 1998 Jan; 67(1):2-4. PubMed ID: 9440366 [No Abstract] [Full Text] [Related]
37. Valvular heart disease associated with fenfluramine-phentermine. Kurz X; Van Ermen A N Engl J Med; 1997 Dec; 337(24):1772-3; author reply 1775. PubMed ID: 9411247 [No Abstract] [Full Text] [Related]
38. Regression and progression of valvulopathy associated with fenfluramine and phentermine. Dahl CF; Allen MR Ann Intern Med; 2002 Mar; 136(6):489. PubMed ID: 11900508 [No Abstract] [Full Text] [Related]
39. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. Strother J; Fedullo P; Yi ES; Masliah E Arch Pathol Lab Med; 1999 Jun; 123(6):539-40. PubMed ID: 10383810 [TBL] [Abstract][Full Text] [Related]